2020
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal Of The American Academy Of Dermatology 2020, 82: 1445-1486. PMID: 32119894, DOI: 10.1016/j.jaad.2020.02.044.Peer-Reviewed Original ResearchMeSH KeywordsAcitretinCyclosporineDrug MonitoringHumansMethotrexatePiperidinesPsoriasisPyrimidinesThalidomideConceptsDermatology–National Psoriasis Foundation guidelinesManagement of psoriasisTreatment of psoriasisChronic inflammatory diseaseFumaric acid estersMultiple organ systemsJoint American AcademyNonbiologic medicationsNonbiologic therapiesInflammatory diseasesFoundation guidelinesNew therapiesAmerican AcademyOrgan systemsMedicationsPsoriasisTherapyTreatmentDiseaseGuidelinesTofacitinibAcitretinPatientsApremilastPrescribers
2014
Methotrexate-Induced Liver Toxicity: Replacing the Liver Biopsy
Strober B. Methotrexate-Induced Liver Toxicity: Replacing the Liver Biopsy. JAMA Dermatology 2014, 150: 862-863. PMID: 24965863, DOI: 10.1001/jamadermatol.2014.681.Peer-Reviewed Original Research
2010
The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory AgentsBiological ProductsDermatologic AgentsDrug MonitoringHumansImmunologic FactorsPsoriasisConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence